Phagenesis, a UK-based medical device company focused on the treatment of dysphagia, has expanded its series B round to $17m. It originally announced a €7m ($9.1m) first close led by Inventages, a life sciences firm backed by Switzerland-based food and nutrition corporation Nestlé, in autumn 2011. Founded in 2007 after it spun off from research…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
